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Abstract
There is a growing body of evidence that implicates matrix metalloproteinases (MMPs) as major players in numerous
diseased conditions. The articular cartilage degradation that is characteristic of rheumatoid arthritis (RA) is believed to be
mediated by the collagenase subfamily of matrix metalloproteinases. The preference of collagenase-3 (CL-3) for collagen type
II makes it a likely candidate in the turnover of articular cartilage and a potential target for drug development. In this study,
RA synovial membrane tissue was shown to express CL-3 mRNA by reverse transcriptase-polymerase chain reaction (RT-
PCR) and protein by immunohistochemistry. Fibroblasts isolated and cultured from RA synovial membrane tissue were
induced to express CL-3 mRNA. CL-3 mRNA was detected after PMA treatment in 16 of the 18 RA synovial membrane
fibroblast cell lines established for this study. These fibroblasts also expressed mRNA for collagenase-1 (CL-1, MMP-1),
membrane type-1 matrix metalloproteinase, gelatinase A, gelatinase B, stromelysin-1, stromelysin-2, TIMP-1, and TIMP-2.
They were further shown to express CL-1 mRNA constitutively and CL-3 mRNA only after stimulation with PMA, IL-1,
TGF-L1, TNF-K, or IL-6 with IL-6sR. These fibroblasts also expressed after induction both CL-1 and CL-3 at the protein
level as determined by Western blot analyses and immunofluorescence. ß 2000 Elsevier Science B.V. All rights reserved.
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diamidino-2-phenylindole; FBS, fetal bovine serum; FITC, £uorescein-5-isothiocyanate; Gel A, gelatinase A, Mr 72 000 gelatinase,
MMP-2; Gel B, gelatinase B, Mr 92 000 gelatinase, MMP-9; IL-1, interleukin-1; IL-6, interleukin-6; IL-6sR, interleukin-6 soluble
receptor; mAb, monoclonal antibody; MMP, matrix metalloproteinase; MT1-MMP, membrane type-1 MMP, MMP-14; pAb, polyclonal
antibody; PBS, phosphate bu¡ered saline; PMA, phorbol 12-myristate 13-acetate; RT-PCR, reverse transcriptase-polymerase chain
reaction; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SL-1, stromelysin-1, MMP-3; SL-2, stromelysin-2,
MMP-10; TBS-TX, Tris bu¡ered saline with 0.1% Triton X-100; TGF-L1, transforming growth factor-L1; TIMP, tissue inhibitor of
metalloproteinases; TNF-K, tumor necrosis factor-K ; TXRD, Texas-red dye
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1. Introduction
The matrix metalloproteinases (MMPs) comprise
an expanding family of zinc and calcium dependent
enzymes (for reviews see [1,2]), which collectively are
able to degrade most of the components of the extra-
cellular matrix. MMPs are powerful enzyme players
in tissue remodeling and wound healing. Alterations
of the levels of MMP expression, activation, and in-
hibition by tissue inhibitors of metalloproteinases
(TIMPs) may contribute to the progression of nu-
merous diseases.
Most MMPs are secreted as zymogens that require
external activation to proteolytically competent
forms. In vitro, MMP activation can result from
treatment with conformational perturbants such as
sodium dodecyl sulfate or (4-aminophenyl)mercuric
acetate, as well as by proteolytic activation with tryp-
sin or other proteases. The MMPs can be inhibited
by the TIMPs and K2-macroglobulin. The ratio of
inhibitors versus MMPs is only one mechanism
that plays a role in controlling the degradation or
the accumulation of the extracellular matrix. Regu-
lation also occurs at the transcriptional level and at
the level of MMP activation. Improper management
of MMP expression and activation has been sug-
gested to play major roles in a number of disease
conditions such as osteoarthritis, rheumatoid arthri-
tis, tumor invasion and metastasis, and Alzheimer’s
disease.
The collagenases, because of their ability to cleave
the helical collagens, are believed to play a major
role in the collagen degradation associated with ar-
thritic conditions. One of the newest members of the
collagenase subfamily is collagenase-3 (CL-3, MMP-
13), which was originally isolated from a breast tu-
mor library [3]. Human CL-3 shares only 50.5% ami-
no acid homology with human collagenase-1 (CL-1),
while it is 86% homologous to the mouse and rat
collagenases [3^5]. CL-3 has been shown to degrade
collagen types I, II, and III, as well as being able to
degrade the cartilage proteoglycan aggrecan [6]. Un-
like CL-1, which has a substrate preference for col-
lagen type III, CL-3 prefers collagen type II which is
the primary collagen found in articular cartilage [7].
Gelatinase B (MMP-9) and membrane type-1 MMP
(MT1-MMP, MMP-14) have both been shown to be
able to activate CL-3 in vitro [7]. In addition, acti-
vation of CL-3 by MT1-MMP is augmented by the
presence of gelatinase A (MMP-2) [7].
In addition to being detected in breast tumors,
CL-3 mRNA has been found in articular cartilage
[8] and in the synovial tissue from patients with os-
teoarthritis or rheumatoid arthritis, but not in nor-
mal synovial tissue [9]. The CL-3 protein has been
detected in synovial £uid and in cartilage from pa-
tients with reactive arthritis or active seropositive
rheumatoid arthritis, but no CL-3 protein could be
detected in the synovial tissue of these patients [8].
Immunohistochemical staining of rheumatoid arthri-
tis and osteoarthritis synovial tissues identi¢ed ¢bro-
blast- and macrophage-like cells that were positive
for CL-3 [10]. It was originally reported in several
studies that cultured human synovial ¢broblasts
could not express CL-3 mRNA or protein [11,12].
Recently, CL-3 mRNA and protein have been found
in pannocytes of the pannus-hard tissue junction of
tissue from RA patient samples [13]. Also in this
recent study, cultured cells from RA tissue were
shown to express CL-1 and CL-3 constitutively and
could be stimulated with tumor necrosis factor-K
(TNF-K) or interleukin-1 (IL-1L) [13]. However,
CL-3 and not CL-1 expression was stimulated by
phorbol 12-myristate 13-acetate (PMA) [13]. In con-
trast in yet another study, the CL-3 mRNA basal
level of human synovial ¢broblasts was not stimu-
lated with PMA [14]. In addition, CL-3 expressed
by synovial ¢broblasts isolated from rabbit synovium
was stimulated with PMA, IL-1L, or TNF-K [15]. As
mentioned above, a clear consensus has not been
reached in regard to the expression and induction
patterns of CL-3 in synovial ¢broblasts.
In this paper, reverse transcriptase-polymerase
chain reaction (RT-PCR) and immunohistochemistry
were utilized to examine the CL-1 and CL-3 expres-
sion in RA synovial membrane tissue. RT-PCR was
also utilized to examine CL-1 and CL-3 mRNA ex-
pression in human RA synovial membrane ¢bro-
blasts. Not only did these synovial ¢broblasts express
mRNA for CL-1, but also CL-3 when induced. Se-
quencing of the RT-PCR fragment veri¢ed that the
primers were speci¢c and that these cells do express
mRNA for CL-3. CL-3 mRNA was induced with
PMA in 16 out of 18 (88.8%) RA cell lines estab-
lished for this study. CL-3 mRNA was also induced
in these synovial membrane ¢broblasts with IL-1,
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TGF-L1, TNF-K, and IL-6 in the presence of IL-
6sR. CL-3 protein expression was also observed in
these RA synovial ¢broblasts after PMA induction
by Western blot analyses and immuno£uorescence.
2. Materials and methods
2.1. CL-3 expression in Escherichia coli, extraction,
and puri¢cation
The CL-3 cDNA was a generous gift from Carlos
Lopez-Otin [3]. The cDNA was removed from
pEMBL19 by HindIII digestion. The insert was
then ligated into the HindIII site of pGEMEX-1
(Promega, Madison, WI). The coding sequence for
gene 10 of pGEMEX was removed by site-directed
mutagenesis using the following oligonucleotide: 5P-
ACTTTAAGAAGGAGATATACATATGCTGCC-
CCTTCCCAGT-3P.
The deletion and the coding sequence for CL-3
was veri¢ed by DNA sequencing. The construct
(pGEMEX-CL-3) was transformed into E. coli
DE3 cells [16] and transcription from the T7 pro-
moter of the expression plasmid was induced after
the cells were grown to a density of 108 cells/ml by
1 mM isopropyl-L-D-thiogalactopyranoside.
After a 2 h expression period at 37‡C, the cells
were harvested by centrifugation and resuspended
in 50 mM Tris-HCl, pH 7.5, 0.2 M NaCl, 5 mM
CaCl2, and 1 WM ZnCl2. Following passage through
a French press at 10 000^15 000 psi in the presence of
1 mM phenylmethylsulfonyl £uoride, the samples
were centrifuged and the pellets washed with 50
mM Tris-HCl, pH 7.5, 0.2 M NaCl, 5 mM CaCl2,
and 1 WM ZnCl2. The washed pellets were extracted
with 6 M urea in 50 mM Tris-HCl, pH 7.5, 0.2 M
NaCl, 5 mM CaCl2, and 1 WM ZnCl2 for 2^3 h at
4‡C on an orbital mixer.
The 6 M urea extracts were passed over a Sepha-
cryl S-200 HR (Pharmacia, Piscataway, NJ) column
(2.5 cmU88 cm) equilibrated with 6 M urea in 50
mM Tris-HCl, pH 7.5, 0.2 M NaCl, 5 mM CaCl2,
and 1 WM ZnCl2. Peak fractions (s 90% pure) were
dialyzed against 50 mM Tris-HCl, pH 7.5, 0.2 M
NaCl, 5 mM CaCl2, and 1 WM ZnCl2 to remove
the urea. Protein concentrations were determined
by the Bradford method [17] using bovine serum al-
bumin as a standard. The puri¢ed recombinant CL-3
was then used to make monoclonal antibodies (mAb)
according to previously described methods [18]. Anti-
CL-3 mAb ID3 was then utilized throughout this
study.
2.2. Other antibodies
Polyclonal (pAb 647) and monoclonal (mAb III12)
anti-CL-1 antibodies have been previously described
and shown to be speci¢c for human CL-1 [19,20].
MT1-MMP pAb 815 was purchased from Chemicon
(Temecula, CA).
2.3. Electrophoretic methods
Samples were resolved on SDS-PAGE gels by the
methods of Laemmli [21] and transferred to nitro-
cellulose membrane by electroblotting for Western
blot analyses. The membranes were blocked with
5% bovine serum albumin in 50 mM Tris-HCl, pH
7.5, and incubated with primary antibody (5 Wg/ml)
in 50 mM Tris-HCl, pH 7.5, 0.5% bovine serum al-
bumin for 1 h at 37‡C. The membranes were then
washed in TBS-TX (50 mM Tris-HCl, pH 7.5, 0.2 M
NaCl, 1% Triton X-100) and subsequently incubated
with peroxidase-conjugated secondary antibody (6.5
Wg/ml) as previously described [18]. Alternatively, en-
hanced chemiluminescence plus kit was utilized as
per the manufacturer (Amersham Pharmacia Bio-
tech, Buckinghamshire, UK).
2.4. Immunohistochemistry
Human synovial membrane tissue was obtained
from RA patients through the University of Alaba-
ma at Birmingham tissue procurement facility. Tissue
sections were prepared and then ¢xed in phosphate
bu¡ered formalin (Fisher Scienti¢c, Pittsburgh, PA),
dehydrated in xylenes, and embedded in para⁄n.
Tissue blocks were cut into 4 Wm sections with a
power microtomer and placed on microscope slides.
The sections were depara⁄nized by heating to 65‡C
for 1 h and subsequent treatments with xylenes. The
tissues were rehydrated by soaking in 100%, 95%,
and then 75% ethanol. Endogenous peroxidase
quenching was carried out with 3.0% hydrogen per-
oxide for 10 min. Samples were stained using 3^6 Wg/
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ml of anti-CL-1 mAb III12, anti-CL-3 mAb ID3, or
anti-vimentin mAb 3400 (Chemicon) and with sec-
ondary antibodies, horseradish peroxidase enzyme
conjugate, and aminoethyl carbazole chromogen
and then developed as per the manufacturer’s in-
structions (Zymed Laboratories, San Francisco,
CA). The samples were then brie£y counterstained
with Mayer’s hematoxylin and mounted in glycerol
vinyl alcohol (GVA) mounting medium (Zymed Lab-
oratories). Images were captured using a SPOT cam-
era and software (Diagnostic Instruments, Birming-
ham, AL).
2.5. RT-PCR
Total RNA was recovered from homogenized
synovial membrane tissue or cells as per the RNeasy
spin mini-column manufacturer’s instructions (Qia-
gen, Valencia, CA). RNA (0.4 Wg) was added to
each RT reaction containing One-Step RT-PCR
mix (Qiagen) and the appropriate PCR primers in
50 Wl total. RT was carried out for 30 min at 50‡C
followed by a 15 min step at 94‡C. PCR was then
performed in a thermocycler programmed for 30
cycles of 1 min at 94‡C, 1 min at 60‡C, and 1 min
at 72‡C. The RT-PCR reaction was mixed with 10 Wl
40% sucrose with bromophenol blue and 8 Wl of
sample was loaded per lane on a 1% agarose gel.
Gels were stained with ethidium bromide and photo-
graphed. The following speci¢c primers were used in
the PCR reactions and the size of the PCR product
in base pairs (bp) are shown.
2.6. Tissue culture
RA synovial membrane tissue was washed with
70% ethanol and minced in phosphate bu¡ered saline
(PBS). The dissected tissue was digested with 1.5 mg/
ml Dispase (Roche, Nutley, NJ) in serum free Dul-
becco’s modi¢ed Eagle’s (DME) medium (Irvine Sci-
enti¢c, Santa Ana, CA). The cells were pelleted, re-
suspended in DME medium supplemented with 10%
fetal bovine serum (FBS), plated, and grown in a 5%
CO2 incubator at 37‡C. The cells were treated with
PMA (Sigma) or cytokines IL-1, IL-6, IL-6 with IL-
6sR, TNF-K, or TGF-L1 (RpD Systems, Minneap-
olis, MN). SW1353 chondrocytes were obtained from
American Type Culture Collection (Rockville, MD)
and maintained in DME medium supplemented with
10% FBS.
2.7. Sequencing of the collagenase-3 PCR fragment
The PCR fragment from RA synovial ¢broblasts
ampli¢ed with the CL-3 speci¢c primers was puri¢ed
using the Qiagen Gel Extraction Kit (Qiagen) and
ligated into the modi¢ed TA vector, pGEM-T Vector
(Promega). The plasmid was ampli¢ed in E. coli
DH5K competent cells. Qiagen Mini-Prep Kits were
used for plasmid puri¢cation. A primer speci¢c for
the T7 promoter (5P-AATACGACTCACTATAG-
GG-3P) and the CL-3 PCR primers were used in
Cyclophilin
(274 bp)
5P-CCGTGTTCTTCGACATT (sense)
5P-GCCAGGACCCGTATGCT (antisense)
CL-1 (721 bp) 5P-GAAGGTGATGAAGCAGCCCAGATGT
(sense)
5P-CAGTTGTGGCCAGAAAACAGAAGTG
AAA (antisense)
CL-3 (517 bp) 5P-GCTTAGAGGTGACTGGCAAC (sense)
5P-CCGGTGTAGGTGTAGATAGGAAC
(antisense)
MT1-MMP
(670 bp)
5P-GATAAACCCAAAAACCCCACCTA
(sense)
5P-CCCTCCTCGTCCACCTCAATG
(antisense)
Gel A (364 bp) 5P-ATCCGTGGTGAGATCTTCTTCTT
(sense)
5P-AGCCAGGATCCATTTTCTTCTT
(antisense)
Gel B (519 bp) 5P-TGCCAGTTTCCATTCATCTTCCAA
(sense)
5P-CTGCGGTGTGGTGGTGGTT (antisense)
TIMP-1
(534 bp)
5P-CCTTCTGCAATTCCGACCTCGTC
(sense)
5P-CGGGCAGGATTCAGGCTATCTGG
(antisense)
TIMP-2
(433 bp)
5P-TGGAAACGACATTTATGGCAACC
(sense)
5-ACAGGAGCCGTCACTTCTCTTGAT
(antisense)
SL-1 (659 bp) 5P-GACACCAGCATGAACCTTGTT (sense)
5P-GGAACCGAGTCAGGTCTGTG
(antisense)
SL-2 (863 bp) 5P-TGCCCAGCAATACCTAGAAAAGTA
(sense)
5P-GGTTCCAGTGGGATCTTCG (antisense)
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modi¢ed Sanger sequencing reactions [22] to se-
quence the CL-3 fragment.
2.8. Western blot of conditioned medium
For detection of CL-3 in the conditioned medium,
SW1353 chondrocytes or synovial membrane ¢bro-
blasts were treated with 1.6U1037 M PMA in serum
free medium for 15 h. The conditioned medium was
removed and 10 ml were lyophilized overnight in a
Freezemobile Lyophilizer (Vitris, Gardiner, NY). It
was then resuspended in 400 Wl of 4 M urea. Equal
volumes of sample and of sample bu¡er were mixed
and 20 Wl total was loaded per lane on 10% SDS-
PAGE gels and analyzed by Western blots.
2.9. Crude membrane extracts
Membrane fractions were extracted using a modi-
¢ed protocol described by Wrenn et al. [23]. In brief,
after a 15 h treatment with PMA in serum free me-
dium, the cells were washed thoroughly with cold
PBS and suspended in isolation bu¡er (20 mM
HEPES pH 7.4, 250 mM sucrose, 2 mM benzami-
dine, 2 mM O-amino-n-caproic acid, 1 mM CaCl2,
1 mM MgCl2). The cells were then lysed with a tight
¢tting dounce and drawn repeatedly through a 25 g
needle and syringe. The cell lysates were then centri-
fuged at 500Ug to pellet the nuclei. Post-nuclear
supernatants were ultracentrifuged at 30 000Ug for
45 min. The resulting pellet was resuspended in SDS-
PAGE loading dye for Western blot analyses.
2.10. Immuno£uorescence
Cells were seeded on glass coverslips and grown to
80% con£uence. Cells were treated with PMA for 15
h. Cells were then washed with PBS and subse-
quently incubated in serum free medium with 1036
M monensin for 3 h. All the samples were immedi-
ately ¢xed with phosphate bu¡ered 10% formalde-
hyde for 1 h at 25‡C. After ¢xation, the cells were
washed with PBS and permeabilized for 1 min at
25‡C with Tris bu¡ered saline with 0.1% Triton X-
100 (TBS-TX). The cells were blocked with 10% nor-
mal goat serum (Zymed Laboratories) in TBS-TX
for 30 min at 25‡C. Primary antibodies to CL-1
and CL-3 were diluted in 10% normal goat serum
in TBS-TX and incubated for 1 h at 25‡C. Fluores-
cein-5-isothiocyanate (FITC) conjugated goat anti-
rabbit and Texas-red dye (TXRD) conjugated goat
anti-mouse secondary antibodies (Zymed Laborato-
ries) were incubated in TBS-TX with 10% normal
goat serum and incubated for 1 h at 25‡C. During
incubation with the secondary antibodies, 5 Wg/ml of
4,6-diamidino-2-phenylindole (DAPI) was used to
counterstain the nuclei. Slides were mounted in Pro-
long Antifade Medium (Molecular Probes, Eugene,
OR) and stored at 320‡C. Images were captured
using an Olympus IX70 microscope equipped with
digital confocal capabilities and IP Lab software
(Signal Analytics, San Jose, CA). Three images
were captured per sample using ¢lters for FITC,
TXRD, and UV. The DAPI images were overlaid
with the FITC or TXRD to yield the ¢nal images.
2.11. PMA and cytokine induction
Cells were washed with PBS and incubated with
either PMA (1.6U1037 M), IL-1 (5 ng/ml), IL-6 (5
ng/ml), IL-6 (5 ng/ml) with IL-6sR (250 ng/ml),
TNF-K (10 ng/ml), or TGF-L1 (10 ng/ml) in serum
free DME. The cells were then washed and RT-PCR
performed as described above. Equal volumes of
each sample were analyzed in a 1% agarose gel and
visualized with ethidium bromide staining.
Fig. 1. Characterization of the anti-CL-3 mAb ID3. Western
blot analyses of PMA stimulated SW1353 chondrocyte condi-
tioned medium demonstrated that these cells express and secrete
CL-1 and CL-3, as well as demonstrated the speci¢city of these
antibodies. Conditioned medium was concentrated, resolved by
SDS-PAGE, transferred to nitrocellulose, and probed with ei-
ther 5 Wg/ml anti-CL-1 mAb III12, 5 Wg/ml anti-CL-3 mAb ID3,
or 5 Wg/ml of each antibody combined.
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3. Results
3.1. CL-3 antibodies
CL-3 was expressed in E. coli, extracted, and pu-
ri¢ed by size-exclusion chromatography to greater
than 90% purity (data not shown). This puri¢ed re-
combinant CL-3 was then used as the antigen to
produce antibodies that recognized CL-3 and did
not cross-react with other MMPs (Fig. 1 and data
not shown). Medium from SW1353 chondrocytes
was concentrated and analyzed by Western blot anal-
yses. Anti-CL-1 mAb III12 detected CL-1 (Fig. 1,
lane CL-1) and anti-CL-3 mAb ID3 detected CL-3
protein expression by these cells (Fig. 1, lane CL-3).
When both antibodies were used together, CL-1 and
CL-3 were readily visualized at slightly di¡erent mo-
lecular weights (Fig. 1, lane CL-1+CL-3). Anti-CL-3
mAb ID3 was then utilized in this study for Western
blots, immuno£uorescence, and immunohistochemis-
try.
3.2. Immunohistochemistry
After embedded RA synovial membrane tissue was
depara⁄nized and rehydrated, sections were then
stained with hematoxylin and eosin or probed with
monoclonal antibodies speci¢c for vimentin, CL-1,
or CL-3 and lightly counterstained with hematoxylin.
Fig. 2 shows tissue sections from a patient in which
isolated ¢broblasts were able to express CL-3 mRNA
and protein. Fig. 2A shows the morphology of the
Fig. 2. Immunohistochemistry of human RA synovial membrane tissue. Panel A presents the overall morphology of human synovial
membrane with a hematoxylin and eosin stain. Panels B, C, and D were probed with monoclonal antibodies speci¢c for vimentin,
CL-1, and CL-3, respectively. Cells which expressed CL-1 and CL-3 protein were found in the periphery of the RA synovial mem-
brane and were ¢broblast-like cells, which where also vimentin positive.
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synovial membrane tissue with hematoxylin and eo-
sin staining. At the periphery of the tissue is a com-
pact yet not contiguous layer of ¢broblasts-like cells
ranging from one to ¢ve cells deep. Blood vessels,
macrophages, and muscle ¢bers were also visible
throughout the tissue. The section in Fig. 2B was
stained with anti-vimentin monoclonal antibody
and shows staining primarily at the periphery of
the tissue. The CL-1 staining pattern is shown in
Fig. 2C and is again primarily at the periphery of
the tissue. Fig. 2D shows the presence of CL-3 pro-
tein also at the periphery of the tissue. Similar stain-
ing patterns were observed in eight of the nine speci-
mens checked and only one specimen stained
negative for CL-3 (data not shown). Control experi-
ments using nonspeci¢c mAbs or no primary anti-
bodies showed no signi¢cant staining (data not
shown).
3.3. RT-PCR of human RA synovial membrane tissue
RNA was isolated directly from synovial mem-
brane tissue from which RA synovial ¢broblasts
were also isolated. Speci¢c RT-PCR products for
cyclophilin, CL-1, and CL-3 were detected in the
synovial membrane tissue (Fig. 3). This demon-
strated that CL-3 mRNA, as well as CL-1 mRNA,
as expected from the immunohistochemistry data
was present in this human RA synovial membrane
tissue.
3.4. MMP and TIMP mRNA expression by
RA synovial ¢broblasts
RA synovial ¢broblasts were isolated from syno-
vial membrane tissue excised from patients with clin-
ical rheumatoid arthritis. RT-PCR was performed on
mRNA isolated from PMA treated or untreated
Fig. 4. RT-PCR of synovial membrane ¢broblasts with and
without PMA. Speci¢c primers ampli¢ed cyclophilin (Cyclo),
collagenase-1 (CL-1), or collagenase-3 (CL-3). CL-1 was consti-
tutively expressed in all the RA synovial membrane ¢broblasts
cell lines and further enhanced by PMA stimulation, whereas
all of the RA synovial membrane ¢broblast cell lines that had
detectable levels of CL-3 mRNA required PMA stimulation.
Fig. 3. RA synovial membrane tissue RT-PCR. mRNA was iso-
lated from fresh RA synovial membrane tissue and RT-PCR
was performed to speci¢cally amplify the positive control cyclo-
philin (Cyclo, 274 bp), collagenase-1 (CL-1, 721 bp), or collage-
nase-3 (CL-3, 517 bp). Products were separated and visualized
in an ethidium bromide stained 1% agarose gel. The tissue ex-
pressed mRNA for both CL-1 and CL-3.
Fig. 5. RT-PCR of MMPs and TIMPs in PMA treated synovial
membrane ¢broblasts. RT-PCR products from PMA treated
RA synovial membrane ¢broblasts were resolved in 1% agarose
gels and stained with ethidium bromide. (A) A synovial mem-
brane ¢broblast cell line in which mRNA for CL-1 and CL-3
was detected. (B) A synovial membrane ¢broblast cell line in
which CL-1 mRNA, but no CL-3 mRNA, was visualized.
mRNA expression was also examined for cyclophilin (Cyclo,
274 bp), membrane type-1 matrix metalloproteinase (MT1-
MMP, 670 bp), gelatinase A (Gel A, 364 bp), gelatinase B (Gel
B, 519 bp), tissue inhibitor of matrix metalloproteinase-1
(TIMP-1, 534 bp), tissue inhibitor of matrix metalloproteinase-2
(TIMP-2, 433 bp), stromelysin-1 (SL-1, 659 bp), and stromely-
sin-2 (SL-2, 863 bp).
BBADIS 61970 9-10-00 Cyaan Magenta Geel Zwart
B.A. Moore et al. / Biochimica et Biophysica Acta 1502 (2000) 307^318 313
early passage (1^3) RA synovial membrane ¢bro-
blasts (Fig. 4). It was routinely observed that these
cells expressed mRNA for CL-3, but only upon in-
duction with PMA (Fig. 4). CL-1 on the other hand
was constitutively expressed and could be stimulated
with PMA (Fig. 4).
RT-PCR was then performed on a total of 18
PMA treated RA synovial ¢broblast cell lines (cell
lines 1^18) established for this study. The control
cyclophilin mRNA was detected in 100% of the sam-
ples as expected. mRNA for MT1-MMP, gelatinase
A, gelatinase B, TIMP-1, TIMP-2, and stromelysin-1
were also detected in 100% of these RA samples.
Stromelysin-2 mRNA was ampli¢ed in 78.9% of
Fig. 6. Immuno£uorescence of CL-1 and CL-3. Two distinct human synovial membrane ¢broblast cell lines were PMA stimulated and
monensin treated prior to ¢xation. All slides were probed with anti-CL-1 pAb 647 and anti-CL-3 mAb ID3 followed by £uorescent
secondary antibodies and then the nuclei were counterstained with DAPI. Panels A and B represent a CL-3 positive RA synovial
membrane ¢broblast cell line, whereas panels C and D represent a CL-3 negative cell line. Images for panels A and C were captured
with a TXRD ¢lter to visualize CL-1. Panel B and D images were captured with the FITC ¢lter to visualize CL-3.
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the samples. CL-1 mRNA was detected in 100% of
the cell lines, while CL-3 mRNA was found in 88.8%
of these samples by RT-PCR. Similar values were
recently obtained for CL-1 (100%) and CL-3 (90%)
from RT-PCR of RA synovial membrane tissues di-
rectly [24]. As seen in Fig. 5A and B, representative
agarose gels illustrate the presence (Fig. 5A) or ab-
sence (Fig. 5B) of mRNA for the MMPs and TIMPs
in RA synovial ¢broblast cell lines 1 and 11, respec-
tively.
3.5. Sequencing of the CL-3 RT-PCR fragment
To ensure the speci¢c ampli¢cation of CL-3, the
PCR product was ligated into a modi¢ed TA vector,
ampli¢ed, and plasmid DNA puri¢ed. The PCR
product was sequenced using a modi¢ed Sanger
method and yielded sequence identical to the pub-
lished sequence (data not shown) for human CL-3
originally isolated from a breast tumor library [3].
3.6. Immuno£uorescence
Immuno£uorescence was used to investigate CL-3
protein expression by individual RA synovial mem-
brane ¢broblasts (Fig. 6). Synovial membrane ¢bro-
blasts from a CL-3 positive cell line (cell line 1) and a
CL-3 negative cell line (cell line 11) were grown to
90% con£uence and induced overnight with PMA.
The cells were then treated with monensin for 3 h
before ¢xation and staining. After treatment with
monensin, the CL-1 and CL-3 staining patterns
were typical of proteins trapped in the golgi appara-
tus. However, £uorescent detection of the CL-3 pro-
tein yielded a reproducible though weaker signal
than for CL-1. Fig. 6 shows the two di¡erent RA
synovial ¢broblasts cell lines ¢xed and stained for
CL-1 or CL-3 and counterstained with DAPI. Fig.
6A shows the presence of CL-1 in synovial ¢broblast
cell line 1 and Fig. 6C shows that cell line 11 also
expressed CL-1. Fig. 6B depicts the presence of the
CL-3 protein in cell line 1 while Fig. 6B shows that
cell line 11 did not express the CL-3 protein. A hun-
dred cells from cell line 1 were counted in three sam-
ples and an average of 67 cells per sample were CL-1
positive (67%), while 30 cells per sample were CL-3
positive (30%). Individual cells were seen expressing
both CL-1 and CL-3, yet some cells expressed only
CL-1 or CL-3 (data not shown). The protein expres-
sion of CL-1 and CL-3 seen in Fig. 6 correlates well
with the RT-PCR performed on these two cell lines
(Fig. 5). Fig. 6A and B represent the same cells in
Fig. 5A (cell line 1) and Fig. 6C and D represent the
cells shown in Fig. 5B (cell line 11).
3.7. Western analyses of CL-1 and CL-3
To further examine CL-1 and CL-3 protein expres-
sion, conditioned culture medium and membrane ex-
tracts from cell line 1 (CL-3 positive) were examined
by Western blot analyses. Synovial ¢broblasts were
grown to 90% con£uence and induced with PMA in
serum free medium for 15 h. The medium was then
removed and concentrated. The remaining cell
monolayer was used to isolate cell membrane ex-
tracts as described in Section 2. Anti-CL-3 mAb
ID3 and anti-CL-1 mAb III12 were then used for
Western blot analyses. The conditioned medium
was shown to contain both CL-1 and CL-3 (Fig.
7A). The association of CL-3 with the cell membrane
and/or with MT1-MMP was examined since MT1-
MMP has been shown to activate CL-3 in vitro [7].
Also in recent studies in the lab, CL-3 has been ob-
served to be associated with crude membrane ex-
tracts from a squamous cell carcinoma (SCC-25)
Fig. 7. Western blot analyses of conditioned medium (A) and
membrane extracts (B) from PMA stimulated RA synovial
membrane ¢broblasts. (A) Concentrated conditioned medium
was resolved by SDS-PAGE, transferred to nitrocellulose, and
probed with anti-CL-1 mAb III12 or anti-CL-3 mAb ID3. Both
CL-1 and CL-3 were found in the conditioned medium from
PMA stimulated cells. (B) Crude membrane extracts were also
resolved by SDS-PAGE, blotted, and probed with anti-CL-3
mAb ID3 or anti-MT1-MMP pAb 815. The MT1-MMP protein
was detected in the crude membrane extracts, yet no CL-3 pro-
tein was detected.
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from American Type Culture Collection. However,
in the cell membrane extracts from the RA synovial
¢broblasts, a strong signal for MT1-MMP was visu-
alized while no CL-3 protein was seen (Fig. 7B).
3.8. PMA and cytokine induction
CL-3 positive cells (cell line 1) were treated with
either PMA (1037 M), IL-1 (5 ng/ml), IL-6 (5 ng/ml),
IL-6 (5 ng/ml) with IL-6sR (250 ng/ml), TNF-K (10
ng/ml), or TGF-L1 (10 ng/ml) in serum free DME.
After RT-PCR was performed as described above,
equal aliquots were analyzed in a 1% agarose gel
and visualized with ethidium bromide staining. In
cells not stimulated with PMA or cytokines, CL-1
and not CL-3 was constitutively expressed by the
RA synovial membrane ¢broblasts (Fig. 8). CL-3
mRNA in these cells was induced by PMA, IL-1,
TNF-K, TGF-L1, or IL-6 with IL-6sR. IL-6 alone
did not induce CL-3 mRNA expression. As noted
before, CL-1 was constitutively expressed and only
PMA, IL-1, or IL-6 with IL-6sR increased CL-1
mRNA levels above the basal level. TNF-K had little
e¡ect on CL-1 mRNA expression, while TGF-L1
appeared to down regulate CL-1 expression.
4. Discussion
The degradation of articular cartilage is a charac-
teristic of rheumatoid arthritis. Since MMPs are ex-
tremely e⁄cient in cleaving cartilage components,
they have been implicated in the pathogenesis of
rheumatoid arthritis. The collagenase MMP subfam-
ily members, CL-1 and CL-3, have both been sug-
gested to play a role in this degradation. In addition,
it has recently been shown that CL-3 has a higher
activity than CL-1 against type II collagen [7], which
is the major component of articular cartilage.
CL-3 mRNA has been detected in human articular
cartilage [8], as well as in human synovial membranes
[9]. In early studies, no CL-3 mRNA could be de-
tected in cultured human synovial ¢broblasts but
could be detected in cultured human chondrocytes
[11,12,25]. In contrast, CL-3 mRNA and protein
could be detected and induced with PMA in cultured
rabbit synovial ¢broblasts [15]. Recently, it was
shown that synovial ¢broblasts did express CL-3
mRNA constitutively and that PMA could stimulate
CL-3 above basal levels [13]. However, another re-
cent study showed that in synovial ¢broblasts CL-3
mRNA levels was una¡ected by PMA treatment [14].
Therefore, the purpose of this study was to further
examine the expression and/or induction of CL-3 in
human RA synovial membrane ¢broblasts.
Immunohistochemistry demonstrated that the CL-
3 protein was present in RA synovial membrane tis-
sue (Fig. 2). As seen in Fig. 2C and D, CL-1 and CL-
3 proteins were detected at the periphery of this tis-
sue in the synovial membrane lining cells. These cells
were also vimentin positive cells. Previously, in situ
hybridization of RA synovial tissue showed the pres-
ence of CL-1 and CL-3 mRNA in these peripheral
¢broblast-like cells [14]. It was observed by RT-PCR
that CL-3 mRNA was present as expected in this RA
synovial membrane tissue (Fig. 3). This observation
that CL-3 mRNA was present in RA synovial mem-
brane tissues allowed for the further examination of
CL-3 expression and induction by cells isolated from
these tissues.
RT-PCR of PMA stimulated early passage human
RA synovial ¢broblasts demonstrated that these cells
Fig. 8. PMA and cytokine induction in RA synovial membrane ¢broblasts. RT-PCR products cyclophilin (Cyclo), collagenase-1 (CL-
1), and collagenase-3 (CL-3) were ampli¢ed from RA synovial ¢broblasts treated with serum free medium only, PMA, human IL-1,
human TNF-K, human TGF-L1, human IL-6, or human IL-6 with the IL-6sR. Products were resolved and visualized in an ethidium
bromide stained 1% agarose gel. CL-3 mRNA was readily induced with PMA, IL-1, TNF-K, TGF-L1, or IL-6 with IL-6sR. Whereas,
CL-1 mRNA was stimulated with PMA, IL-1, and IL-6 with IL-6sR.
BBADIS 61970 9-10-00 Cyaan Magenta Geel Zwart
B.A. Moore et al. / Biochimica et Biophysica Acta 1502 (2000) 307^318316
could express mRNA for CL-3. The cloning and se-
quencing of the CL-3 PCR fragment veri¢ed that
these cells do express mRNA for CL-3 and that it
was not the product of mistaken ampli¢cation of
another mRNA. It was observed that 16 of the 18
(88.8%) established synovial membrane ¢broblast cell
lines could express mRNA for CL-3 only when in-
duced, whereas 18 of these cell lines expressed
mRNA for CL-1 (100%) whether induced or not.
mRNA for MT1-MMP, gelatinase A, gelatinase B,
TIMP-1, TIMP-2, and stromelysin-1 was detected in
100% of the samples after PMA induction. Strome-
lysin-2 mRNA was ampli¢ed in 78.9% of the PMA
treated cells. The presence of these MMPs known to
be activators of CL-3 such as MT1-MMP and gelat-
inase B suggest that this environment is conducive to
CL-3 activation in vivo and thus CL-3 may be an
important mediator in RA pathogenesis. It was
found that 16 of 18 cell lines expressed CL-3
mRNA only upon stimulation with PMA or various
cytokines. The mRNA expression pro¢les of these
MMPs from these stimulated RA synovial mem-
brane ¢broblasts were similar to the expression pro-
¢les of these MMPs observed in RA synovial mem-
brane tissues [24]. CL-1 mRNA was detected in this
study in 100% of the cell lines checked and similarly
detected in 100% of the RA membrane tissues inves-
tigated in the Konttinen et al. study [24]. They de-
tected CL-3 mRNA in 90% of the RA membrane
tissues checked [24], while CL-3 mRNA was detected
in 88.8% of the RA synovial membrane ¢broblast
cell lines established for this study. This correlation
between CL-3 expression in RA tissue and in the
cultured cells of this study suggests that RA synovial
membrane ¢broblasts could be a source of the CL-3
found in vivo. It was also observed that the two cell
lines that failed to express CL-3 did express all the
other MMPs and TIMPs checked (data not shown).
Since RT-PCR is an extremely sensitive procedure,
the ability of these cells to make detectable levels of
the CL-3 protein was addressed. Immuno£uores-
cence was utilized to demonstrate that these cells
could express the CL-3 protein and to examine the
expression of CL-3 by individual cells. Fig. 6 shows
the two di¡erent RA synovial membrane ¢broblasts
cell lines that were examined for CL-1 and CL-3
protein expression. CL-1 and CL-3 were detected in
cell line 1 and their expression is shown in Fig. 6A
and B, respectively. The CL-3 protein staining ap-
peared to be less intense than the staining of the
CL-1 protein. Also, fewer cells stained positive for
CL-3 (30%) than the number of cells that stained
positive for CL-1 (67%). It was observed that some
of these cells stained positive for both CL-1 and CL-
3, while other cells stained positive for either CL-1 or
CL-3 (data not shown). Staining of RA synovial
membrane ¢broblast cell line 11 detected the CL-1
protein (Fig. 6C), whereas no CL-3 protein was de-
tected (Fig. 6D). Fig. 6C and D demonstrated fur-
ther that the anti-CL-3 mAb ID3 did not cross-react.
Western blots of conditioned medium from RA
synovial ¢broblast cell line 1 detected the CL-1 pro-
tein and CL-3 protein (Fig. 7A). Further analyses by
Western blots of membrane extracts failed to show
any CL-3 protein associated with the membrane and/
or MT1-MMP (Fig. 7B). This was in contrast to
recent results in the laboratory in which Western
blot analyses of crude membrane extracts from
SCC-25 cells detected CL-3 associated with the mem-
branes along with MT1-MMP (unpublished data).
Although it is possible that CL-3 might be associated
with the membrane or with MT1-MMP and be acti-
vated by it, this interaction may be very transient
and di⁄cult to detect.
PMA and cytokine induction of CL-3 mRNA has
been studied in several cell lines. Cultured human
chondrocytes have been shown to express CL-3
mRNA upon induction with a combination of IL-
1L and TNF-K [11,25]. In the embryonic ¢broblast
cell line KMS-6, CL-3 mRNA expression had to be
induced by TGF-L1, IL-1, or PMA [26]. In endome-
trial ¢broblasts, CL-3 mRNA was not detected even
after treatment with TNF-K, IL-1, or IL-6 [27]. Ad-
ditionally in vivo, IL-6 and TNF-K have been local-
ized to the synovial lining cells in the same location
[28] in which CL-3 was visualized by immunohisto-
chemistry (Fig. 3). The RA synovial membrane ¢bro-
blasts in this study responded to PMA, IL-1, TNF-K,
TGF-L1, or IL-6 with IL-6sR with increased CL-3
mRNA expression. These cells did not constitutively
express CL-3, but required stimulus for CL-3 expres-
sion. This suggests that RA synovial membrane ¢-
broblasts could be a CL-3 source in vivo since in
normal synovial tissue CL-3 is not found and the
in£ammatory cytokines are in much lower doses
than in RA tissue [8].
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It should be emphasized that the ability of colla-
genases, as well as other matrix metalloproteinases,
to cleave substrate is contingent on their activation.
Therefore, even a small amount of active enzyme
may be detrimental, whereas a large amount of un-
activated enzyme has no degrading activity. The CL-
3 produced by these synovial membrane ¢broblasts
appeared to be present with other MMPs in an en-
vironment that is conducive to CL-3 activation.
Therefore, CL-3 production by RA synovial mem-
brane ¢broblasts requires further investigation to de-
termine its activation status and exact role in the
pathogenesis of rheumatoid arthritis.
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